Biology of cancer

>> ON BEHALF OF THE NIH DIRECTOR, IT'S MY PLEASURE TO INTRODUCE TODAY'S NIH DIRECT DIRECTOR'S SEMINAR SPEAKER, CRAIG THOMPSON. DR. THOMPSON IS PRESIDENT AND CHIEF...

My name is Johnny Brown and I live in Belfast. I'm a GP by profession. We met playing badminton. Linda was 15 and I was 18 and we both then played badminton all our lives together. We would...

>>> DR. DAVID MARGILETH: The Oncotype DX has I think changed the treatment decisions in patients with hormone receptor-positive, lymph node-negative, HER2-negative breast cancer....

Jean Campbell: I think that the woman needs to be reassured that first of all there are family members who love her and who would want to be there for her, and they would want the opportunity to be...

Rick Baehner: Now, now that you have been newly diagnosed with DCIS, you should talk with either your surgeon or your radiation oncologist about ordering the test. Your surgeon or radiation oncologist...

So how has the Oncotype genetic test helped our patients and changed the way we practice. This is a useful test, this genetic test, to try to predict the aggressiveness of the tumor. And I think the...

So the Oncotype DX test needs to be ordered by a physician and depending upon the patient's situation, a physician may suggest it to help make a decision about whether or not the patient is a...

>>>Dr. Margileth: One of the more common chemotherapies that we give for HER2 positive cancer is a regimen known as TCH. That consists of Taxotere, Carboplatin and Herceptin. Two...

Rick Baehner, M.D.: Let me tell you about a recent experience with a patient who received a DCIS score. The patient was 58 years old. She had an abnormal mammogram that showed calcifications. She had...

THE PRESIDENT: Thanks, Michael. I appreciate you joining us. I love coming to the NIH, it is an amazing place. It is an amazing place because it is full of decent, caring, smart people, all aiming to...